Auric Goldfinger's Short List Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scion who wrote (19311)	9/22/2010 10:05:43 AM
From: scion	of 19428

Sanofi's Blood Vessel Drug Fails Trial SEPTEMBER 22, 2010, 9:48 A.M. ET By MIMOSA SPENCER online.wsj.com PARIS—French drug maker Sanofi-Aventis said Wednesday its experimental blood-vessel medicine NV1FGF failed to meet its target in a late-stage clinical trial. The treatment failed in a Phase III study to demonstrate superiority compared to a placebo in preventing major amputation or death for patients of critical limb ischemia, Sanofi said. Critical limb ischemia is characterized by the obstruction of arteries which decreases blood flow to hands, legs and feet. Full results of the trial will be presented at the American Heart Association Congress on November 16 in Chicago. NV1FGF was licensed by Sanofi from Vical Inc. Vical in 2007 said Sanofi expected to file the drug candidate for market approval sometime this year. Sanofi said on Wednesday it is now evaluating all options on development of the treatment. Analysts said the NV1FGF news was negative for Sanofi, albeit minor. "Even if it's disappointing, it's not a total surprise because we knew this project was risky," said Jean-Jacques Le Fur, analyst with Oddo Securities in a research note Wednesday. He had projected the drug's sales potential at €355 million ($469.8 million) a year. Write to Mimosa Spencer at mimosa.spencer@dowjones. online.wsj.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next